LISTSERV - IRIS Archives - LISTSERV.ICORS.ORG

IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG

	LISTSERV Archives
	IRIS Home

	Log In
	Register

	Subscribe or Unsubscribe

	Search Archives

Options:	Use Forum View Use Monospaced Font Show Text Part by Default Show All Mail Headers
Message:	[<< First] [< Prev] [Next >] [Last >>]
Topic:	[<< First] [< Prev] [Next >] [Last >>]
Author:	[<< First] [< Prev] [Next >] [Last >>]

Subject:	Abilify approved for 10 - 17 year olds
From:	Sylvia Caras <[log in to unmask]>
Reply To:	[log in to unmask]
Date:	Mon, 3 Mar 2008 15:19:31 -0800
Content-Type:	text/plain
Parts/Attachments:	text/plain (22 lines)

U.S. Food and Drug Administration Approves Abilify (aripiprazole) for 
the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar 
I Disorder in Pediatric Patients (10 to 17 Years of Age)

 From the PharmaLive.com News Archive - Feb. 29, 2008
- Otsuka-sponsored Study Evaluated Use of ABILIFY In This Patient 
Population -

TOKYO and PRINCETON, N.J., February 29, 2008 /PRNewswire/ -- Otsuka 
Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company announced 
today that the U.S. Food and Drug Administration (FDA) approved the 
supplemental New Drug Application for ABILIFY(R) (aripiprazole) for the 
acute treatment of manic and mixed episodes associated with Bipolar I 
Disorder, with or without psychotic features in pediatric patients (10 
to 17 years old). ABILIFY has been approved for the acute and 
maintenance treatment of manic and mixed episodes associated with 
Bipolar I Disorder with or without psychotic features ...



Powered by LSoft's LISTSERV(R) list management software

ATOM RSS1 RSS2

LISTSERV.ICORS.ORG